Human health and medicine

Quetiapine

Quetiapine (Seroquel) is an atypical antipsychotic approved in 1997 for schizophrenia and bipolar disorder, with XR adjunctive MDD use; D2/5HT2 antagonism, 7-hour half-life, CYP3A4 metabolism.

Quimi-Hib is a Cuban conjugate vaccine against Haemophilus influenzae type b, the first commercial vaccine made with a chemically synthesized antigen, developed at Cuba's Center for Genetic Engineering and Biotechnology and registered in 2003.

Quinagolide

Quinagolide (CV 205-502, Norprolac) is a non-ergot selective dopamine D2 receptor agonist taken once daily for hyperprolactinemia and prolactinoma, mainly in Europe; UK tablets discontinued in 2026.

Oct 20, 2026

Quinestrol

Quinestrol is a long-acting synthetic estrogen, the 3-cyclopentyl ether of ethinyl estradiol, formerly marketed as Estrovis and now used mainly in rodent fertility control research.

Quinethazone

Quinethazone (Hydromox) is a quinazoline-derived thiazide-like diuretic and antihypertensive, FDA-approved April 10, 1963 (NDA 013264, Lederle, 50 mg tablet), acting via distal tubule Na-Cl cotransporter inhibition; now discontinued.

Oct 20, 2026

Quinfamide

Quinfamide (WIN-40014, Quinfamida) is a dichloroacetyl tetrahydroquinoline luminal amebicide for intestinal amebiasis, given as one-day 300 mg adult or single 4.3 mg/kg pediatric doses; marketed mainly in Mexico, not FDA approved.

Quinidine

Quinidine, D-isomer of quinine from cinchona bark, is a class IA antiarrhythmic (sodium and potassium channel blocker) once standard for atrial fibrillation, now limited by proarrhythmia and mortality signals but used in Brugada syndrome and idiopathic ventricular fibrillation.

Quinine

Quinine is an alkaloid from the bark of South American cinchona trees, the first effective malaria treatment and now a second- or third-line antimalarial and tonic water ingredient.

Quinolone antibiotic

Quinolone antibiotics (fluoroquinolones such as ciprofloxacin) are synthetic broad-spectrum antibiotics inhibiting bacterial DNA gyrase and topoisomerase IV; first quinolone nalidixic acid, 1962, from chloroquine synthesis; EU restricted the class in 2019 over disabling side effects.

Oct 15, 2026

Quinpirole

Quinpirole (LY 171555) is a pyrazoloquinoline compound acting as a full agonist at dopamine D2 and D3 receptors, used in research as the reference full agonist.

Quinupristin

Quinupristin, a semisynthetic group B streptogramin from pristinamycin I, is the 30:70 partner of dalfopristin in Synercid, an intravenous ribosome-targeting antibiotic once approved for vancomycin-resistant E. faecium, now discontinued in the US.

Quitline

A quitline is a free, confidential telephone service that helps tobacco users quit through counseling by trained staff, often combined with free nicotine replacement therapy.

Quizartinib

Quizartinib (Vanflyta), a type II FLT3-ITD kinase inhibitor by Daiichi Sankyo, FDA-approved July 2023 with chemotherapy for newly diagnosed FLT3-ITD-positive AML; QuANTUM-First doubled median survival but carries QT/REMS cardiac restrictions.

QX027N, TSLP×IL-13 bispecific antibody

QX027N (WIN027), a long-acting anti-TSLP×IL-13 bispecific antibody by Qyuns Therapeutics (2509.HK), in Phase I/II for atopic dermatitis, asthma, COPD, and CRSwNP; ex-China rights licensed to Windward Bio's LE2025 for up to US$700 million plus royalties.

Qyuns TSLP/IL-33 bispecific antibody (licensed to Roche)

QX031N (RG6981) is Qyuns Therapeutics' long-acting bispecific antibody targeting TSLP and IL-33 for COPD and asthma, licensed globally to Roche in October 2025 for $75 million upfront plus up to $995 million in milestones; Phase I began in New Zealand in 2026.

R-CHOP regimen

R-CHOP is a combination immunochemotherapy regimen pairing the antibody rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone; standard first-line treatment for diffuse large B-cell lymphoma since 2006, curing roughly 60 to 70% of patients.

R-DHAP regimen

R-DHAP is a combination chemotherapy regimen of rituximab with dexamethasone, high-dose cytarabine, and cisplatin, used mainly as salvage therapy for relapsed CD20-positive B-cell non-Hodgkin lymphomas such as diffuse large B-cell lymphoma, usually before stem cell transplant.

R-EPOCH regimen

R-EPOCH is a six-drug chemoimmunotherapy regimen for B-cell non-Hodgkin lymphoma combining rituximab with etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin, given partly by 96-hour continuous infusion.

R-peak detection

R-peak detection is the signal-processing task of locating the R peak in an electrocardiogram recording so heart rate, rhythm, and beat-to-beat timing can be measured, classically by the 1985 Pan-Tompkins algorithm.

R0 resection

An R0 resection is a cancer operation after which no residual tumor remains, meaning the pathologist finds no tumor cells at or near any resection margin.

R21/Matrix-M malaria vaccine

R21/Matrix-M (CYVAC) is a WHO-recommended, prequalified malaria vaccine for children, developed by Oxford's Jenner Institute with Novavax's Matrix-M adjuvant and made by Serum Institute of India; phase 3 efficacy 75% in seasonal settings, priced under $4 per dose.

RA-BEAM trial

RA-BEAM was a 52-week phase 3 trial of the JAK inhibitor baricitinib in 1307 adults with rheumatoid arthritis inadequately controlled by methotrexate, reported in 2017 in the New England Journal of Medicine.

RAACU trial

RAACU (NCT06002464) is a Vinmec-sponsored, open-label randomized trial in Hanoi testing whether acupuncture added to bilateral continuous erector spinae plane block improves post-hysterectomy pain relief, opioid use, and recovery in 72 women.

Oct 20, 2026

Rabavert

RabAvert, sold abroad as Rabipur, is a purified chick embryo cell rabies vaccine made by Bavarian Nordic, licensed in the United States in 1997 for pre- and post-exposure vaccination.

Rabeprazole

Rabeprazole (Aciphex) is a proton pump inhibitor for GERD, ulcers, H. pylori eradication, and Zollinger-Ellison syndrome, distinguished by mainly non-enzymatic metabolism, low CYP2C19 dependence, and low drug-interaction risk.

Rabies bispecific antibody (Genrix Bio)

Silevimig (斯乐韦米单抗注射液, JinSuXi, GR1801) is Genrix Bio's fully human bispecific antibody targeting rabies virus G protein epitopes I and III, approved by China's NMPA in June 2026 as the first bispecific antibody for rabies passive immunization, non-inferior to HRIG in a 1,200-patient Phase III trial.

Rabies vaccine

Rabies vaccine: inactivated cell-culture vaccine (HDCV, PVRV, PCECV) for pre- and post-exposure prophylaxis against rabies; prompt PEP is 100% effective against a disease killing ~59,000 people yearly.

Rabson-Mendenhall syndrome

Rabson-Mendenhall syndrome (RMS, Mendenhall syndrome), a rare autosomal recessive INSR insulin receptor disorder causing severe insulin resistance, acanthosis nigricans, dental and growth abnormalities, intermediate between Donohue and type A insulin resistance syndromes.

Racecadotril

Racecadotril (acetorphan), an enkephalinase-inhibitor prodrug converted to thiorphan, is an antisecretory antidiarrhoeal used with oral rehydration; approved in France in 1992, evidence in children is mixed.